NCT05835609 - PM534 Administered Intravenously to Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 23, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Patients With Advanced Solid Tumors

Interventions

DRUG

PM534

PM534 drug product is provided as a powder for concentrate for solution for infusion, is a sterile, preservative-free, lyophilized white cake in a single-dose vial for reconstitution prior to intravenous infusion.

Trial Locations (3)

28040

RECRUITING

Hospital Universitario Fundación Jiménez Díaz, Madrid

28050

RECRUITING

Hospital Universitario HM Sanchinarro, Madrid

08023

RECRUITING

HM Nou Delfos, Barcelona